Navigation Links
Cancer Research Institute invests $450k in Oncovir to manufacture powerful immune stimulant
Date:1/21/2011

eement with Oncovir.

"The CVC was established on the fundamental premise that cancer vaccines must include multiple components, including an antigenic target or targets, a delivery system, an immunological stimulant, and a modulator of immunosuppression, or checkpoint blockade, to ensure that the anti-tumor immune response, once aroused, does not shut down prematurely," says Lloyd J. Old, M.D., director of the CRI Scientific Advisory Council and director of the CVC. "Providing funding that will enable a large quantity of clinical grade Poly-ICLC to be manufactured is essential to furthering both Oncovir's and our program's clinical research objectives. Specifically, having a supply of Hiltonol under CVC control will make it possible for our investigators to identify its optimal use within the context of cancer vaccines, particularly in combination with other critical agents, such as antibodies that have the capacity to neutralize cancer-induced immunosuppression. The partnership with Oncovir brings us one step closer to an optimally effective therapeutic cancer vaccine for patients."

As part of its ongoing collaborative program to make Hiltonol available for a variety of therapeutic applications, Oncovir plans to continue to distribute Hiltonol, including the remaining portion of the CVAF-supported batch, to qualified scientists and companies testing next-generation cancer vaccines, as well as to scientists testing promising new immunologic therapies for HIV, malaria, influenza, SARS, hepatitis, and other infectious diseases.

"The CVAF strategy was designed to achieve two principal goalsto increase the number of promising vaccine components in global development, and to facilitate clinical research that will accelerate the refinement of powerful, multi-component cancer vaccines," says Adam Kolom, director of CVAF. "This new partnership with Oncovir will help us advance both, while also adding a valuable agent to our license and intell
'/>"/>

Contact: Brian M. Brewer
bbrewer@cancerresearch.org
212-688-7515
Cancer Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Go figure: Math model may help researchers with stem cell, cancer therapies
2. Uncovering the genetics of prostate cancer
3. Roundworm unlocks pancreatic cancer pathway
4. Researchers unlock how progesterone increases breast cancer risk
5. MicroRNA suppresses prostate cancer stem cells and metastasis
6. Researchers learn why PSA levels reflect prostate cancer progression
7. TGen and Genomic Health Inc. discover genes affecting cancer drug
8. Measles virus, a weapon against cancer?
9. Study identifies new genetic signatures of breast cancer drug resistance
10. An earlier start on diagnosing breast, prostate cancers
11. Early investigations promising for detecting metastatic breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... an essential nutrient similar to the B vitamin and found ... eggs, when given as a dietary supplement in the last ... a lower rate of physiological schizophrenic risk factors in infants ... its potentially therapeutic findings and in its strategy to target ...
... In addition to causing smoggy skies and chronic coughs, soot ... number two contributor to global warming. It,s second only to ... panel., The new study concludes that black carbon, the soot ... to global warming as previously estimated, even by the 2007 ...
... HONOLULU While the iconic Haleakalā silversword plant made a ... a period of substantial climate-related decline. New research published this ... the silversword in its native habitat. Known for its ... single reproductive event at the end of its life, at ...
Cached Biology News:Choline supplementation during pregnancy presents a new approach to schizophrenia prevention 2International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3Global warming may have severe consequences for rare Haleakalā silverswords 2
(Date:8/31/2015)... SAN FRANCISCO, Calif. , Aug. 31, 2015 /PRNewswire/ ... the discovery and development of novel cancer immunotherapies, announced ... M.D., Ph.D., as Chief Executive Officer and William ... Wong and Ho join an experienced management team led ... Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... , ... August 31, 2015 , ... There’s a new ... Minerva is the first commercially available new FDA approved system in the last 14 ... of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction ...
(Date:8/28/2015)... ... 28, 2015 , ... Proove Biosciences , a commercial ... Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM event ... focus on evidence-based research and clinical application, the event gathered industry thought leaders ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") ... ended July 31, 2011. Third - ... and Recent Events Net sales increased 33.6% ...
... Inc. (Nasdaq: SGMO ) announced today that ... overview of the company,s business strategy at 7:30 am ... 2011 Global Life Sciences Conference which will be held ... Nichol, M.B., Ch.B., Sangamo,s executive vice president of research ...
... Pa., Sept. 14, 2011 Tengion, Inc. (NASDAQ: ... Brian Davis, Vice President Finance and Chief Financial Officer of ... Conference on Monday, September 19, 2011, at 1:30 pm EDT. ... be accessed under "Calendar of Events" in the Investors section ...
Cached Biology Technology:China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 2China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 3China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 4China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 5China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 6China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 7China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results 8Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Tengion to Present at UBS Global Life Sciences Conference 2
Glycerokinase; from Bacillus stearothermophilus...
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... enzyme that catalyzes the conversion,of starch ... maltotriose and,dextrins. The level of a-amylase ... are of clinical importance,1-3 while plant ... industry.4, The EnzChek Amylase Assay Kit ...
Biology Products: